ServiceNow, Vertex Pharmaceuticals And More: CNBC's 'Final Trades' - iShares Core S&P Small-Cap ETF ( ARCA:IJR ) , ServiceNow ( NYSE:NOW )
On CNBC's "Halftime Report Final Trades," on Thursday, Jason Snipe, founder and chief investment officer of Odyssey Capital Advisors, said he likes ServiceNow, Inc. ( NYSE:NOW ) , which is down 14% year-to-date.
Is Invesco Biotechnology & Genome ETF ( PBE ) a Strong ETF Right Now?
Smart Beta ETF report for ...
3 Growth Stocks That Could Be 10-Baggers in 10 Years
Air taxis, quantum computing, and gene editing are all promising technologies to invest in for the long haul.
Vertex Pharmaceuticals ( VRTX ) Exceeds Market Returns: Some Facts to Consider
The latest trading day saw Vertex Pharmaceuticals (VRTX) settling at $408.85, representing a +1.15% change from its previous close.
Apple To Rally Around 17%? Here Are 10 Top Analyst Forecasts For Thursday - Acuity ( NYSE:AYI ) , Apple ( NASDAQ:AAPL )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Morgan Stanley raised Acuity Inc. ( NYSE:AYI ) price target from $365 to $425.
Looking At CRISPR Therapeutics's Recent Unusual Options Activity - CRISPR Therapeutics ( NASDAQ:CRSP )
High-rolling investors have positioned themselves bearish on CRISPR Therapeutics ( NASDAQ:CRSP ) , and it's important for retail traders to take note. \This activity came to our attention today through Benzinga's tracking of publicly available options data.
What Does the Market Think About Vertex Pharmaceuticals Inc? - Vertex Pharmaceuticals ( NASDAQ:VRTX )
Vertex Pharmaceuticals Inc's ( NYSE:VRTX ) short interest as a percent of float has risen 11.25% since its last report. According to exchange reported data, there are now 4.05 million shares sold short, which is 1.78% of all regular shares that are available for trading.
Could This Beaten-Down Stock Help You Become a Millionaire?
The company would need to maintain the strong momentum it's had this year for a long time.
5 Top Stocks to Buy in October
These five stocks are underperforming the S&P 500 in 2025, but have what it takes to reward investors over the long term.
Vertex Pharmaceuticals ( VRTX ) Surpasses Market Returns: Some Facts Worth Knowing
In the most recent trading session, Vertex Pharmaceuticals (VRTX) closed at $385.74, indicating a +1.01% shift from the previous trading day.
Vertex ( VRTX ) Is Considered a Good Investment by Brokers: Is That True?
Based on the average brokerage recommendation (ABR), Vertex (VRTX) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
Vertex Pharmaceuticals ( VRTX ) Ascends While Market Falls: Some Facts to Note
In the closing of the recent trading day, Vertex Pharmaceuticals (VRTX) stood at $381.87, denoting a +1.39% move from the preceding trading day.
Vertex Pharmaceuticals Incorporated ( VRTX ) is Attracting Investor Attention: Here is What You Should Know
Zacks.com users have recently been watching Vertex (VRTX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
CrowdStrike To Rally Around 26%? Here Are 10 Top Analyst Forecasts For Thursday - Ameresco ( NYSE:AMRC ) , CME Group ( NASDAQ:CME )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Scotiabank cut Freeport-McMoRan Inc. ( NYSE: FCX ) price target from $55 to $45.
This Chewy Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday - Adient ( NYSE:ADNT ) , Chewy ( NYSE:CHWY )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
My 3 Favorite Stocks to Buy Right Now
Uncertainty is in the air. But these stocks inspire confidence.
CRSP & Sirius Begin Dosing in Thromboembolic Disorder Study in EU
CRISPR Therapeutics and Sirius dose the first patient in a phase II study of SRSD107 for thromboembolic disorders in Europe.
CRISPR Therapeutics and Sirius Therapeutics Announce First Patient Dosed in Phase 2 Trial of SRSD107 for Thromboembolic Disorders in Europe
ZUG, Switzerland and BOSTON and SAN DIEGO and SHANGHAI, Sept. 22, 2025 ( GLOBE NEWSWIRE ) -- CRISPR Therapeutics ( NASDAQ: CRSP ) , a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, and Sirius Therapeutics, a clinical stage biotech company ...
CRISPR Therapeutics and Sirius Therapeutics Announce First Patient Dosed in Phase 2 Trial of SRSD107 for Thromboembolic Disorders in Europe - CRISPR Therapeutics ( NASDAQ:CRSP )
ZUG, Switzerland and BOSTON and SAN DIEGO and SHANGHAI, Sept. 22, 2025 ( GLOBE NEWSWIRE ) -- CRISPR Therapeutics CRSP, a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, and Sirius Therapeutics, a clinical stage biotech company developing ...
Healthcare Stocks Are at an Historic Low and a Turnaround Is on the Horizon
There is a "for sale" sign on the sector, and these two stocks look particularly attractive at their current levels.
Vertex Pharmaceuticals ( VRTX ) Declines More Than Market: Some Information for Investors
In the closing of the recent trading day, Vertex Pharmaceuticals (VRTX) stood at $387.15, denoting a -1.08% move from the preceding trading day.
2 Growth Stocks to Buy and Hold Forever
Look beyond the recent headwinds these two have faced.
Vertex Plunges Around 24% in Six Months: How to Play the Stock
Vertex shares fall nearly 24% in six months on pipeline setbacks but strong CF sales and new launches may shape the future.
Why This Biotech Company Could Be a Growth Stock Powerhouse
The stock has soared in the triple-digits over the past decade.
NJ Healthy Aging Summit to Promote Wellness, Prevention, and Safer Pain Management for Older Adults
Atlantic City, NJ, Sept. 16, 2025 ( GLOBE NEWSWIRE ) -- In an effort to educate an older adult population that has felt the impact of the opioid epidemic, the Partnership for a Drug-Free New Jersey will host the "NJ Healthy Aging Summit: Opioid Safety & Alternatives" from 9:30 a.m. to 3 p.m. on ...
1 Reason Wall Street Is Obsessed With Vertex Pharmaceuticals
Here's why you can't find a Wall Street analyst who will tell you to sell this stock.
Vertex Pharmaceuticals Incorporated ( VRTX ) Is a Trending Stock: Facts to Know Before Betting on It
Zacks.com users have recently been watching Vertex (VRTX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
3 Absurdly Cheap Stocks to Buy for the Long Haul
They trade at some incredibly low earnings multiples.
Claire's Place Foundation's 11th Annual Glow Ride for CF Lights Up Hermosa Beach, Sept. 20
Los Angeles, CA, Sept. 11, 2025 ( GLOBE NEWSWIRE ) -- Grab your bikes, skates or boards and get ready to light up the night! Claire's Place Foundation invites families, friends and fun-seekers of all ages to join the 11th Annual Glow Ride for Cystic Fibrosis on Saturday, September 20, 2025, at ...
Here's How Much You Would Have Made Owning Vertex Pharmaceuticals Stock In The Last 15 Years - Vertex Pharmaceuticals ( NASDAQ:VRTX )
Vertex Pharmaceuticals VRTX has outperformed the market over the past 15 years by 4.73% on an annualized basis producing an average annual return of 17.22%. Currently, Vertex Pharmaceuticals has a market capitalization of $100.71 billion.
Cathie Wood Goes Bargain Hunting: She Just Bought 2 Stocks That Wall Street Thinks Will Climb 50% and 190%
These companies are reaching key milestones.
Vertex Pharmaceuticals ( VRTX ) Stock Slides as Market Rises: Facts to Know Before You Trade
In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $388.55, marking a -2% move from the previous day.
NJ Healthy Aging Summit to Spotlight Opioid Safety and Alternatives for Older Adults
ATLANTIC CITY, Sept. 04, 2025 ( GLOBE NEWSWIRE ) -- A conference later this month will examine the keys to healthy aging and the challenges that prescribed opioids and opioid dependency pose to the older adult population. "NJ Healthy Aging Summit: Opioid Safety & Alternatives" will be held from ...
Why This Biotech Company Could Be a Growth Stock Powerhouse
Recent developments aren't as devastating to the company's prospects as some might think.
Why Is Vertex ( VRTX ) Up 6.9% Since Last Earnings Report?
Vertex (VRTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Editas Nominates EDIT-401 as Lead In Vivo Therapy for High Cholesterol
EDIT nominates EDIT-401, a one-time in vivo gene editing therapy, as its lead pipeline candidate to cut the risk of elevated cholesterol.
Here's How Much You Would Have Made Owning Vertex Pharmaceuticals Stock In The Last 20 Years - Vertex Pharmaceuticals ( NASDAQ:VRTX )
Vertex Pharmaceuticals VRTX has outperformed the market over the past 20 years by 8.01% on an annualized basis producing an average annual return of 16.51%. Currently, Vertex Pharmaceuticals has a market capitalization of $100.60 billion.
Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development Candidate
EDIT-401 achieved ~90% mean LDL-C reduction with single dose in non-human primates ...
3 No-Brainer Stocks to Buy Right Now
Investing in these pharmaceutical stocks is an easy decision.
My 2 Favorite Stocks to Buy Right Now
Looking for good investing ideas? These two stocks could be huge winners for long-term investors.
Can CRSP's In Vivo Pipeline Aid Long-Term Growth Beyond Casgevy?
CRISPR Therapeutics pushes beyond Casgevy with in vivo programs like CTX310, CTX320 and plans for two more studies by 2025-end.
CRSP vs. BEAM: Which Gene Editing Stock Holds More Potential Right Now?
CRISPR Therapeutics gains momentum with Casgevy sales and a broader pipeline, while Beam Therapeutics advances base-editing therapies still in early stages.
What's Driving the Market Sentiment Around Vertex Pharmaceuticals? - Vertex Pharmaceuticals ( NASDAQ:VRTX )
Vertex Pharmaceuticals's VRTX short percent of float has fallen 15.1% since its last report. The company recently reported that it has 3.70 million shares sold short, which is 1.63% of all regular shares that are available for trading.
Vertex Pharmaceuticals Incorporated ( VRTX ) is Attracting Investor Attention: Here is What You Should Know
Zacks.com users have recently been watching Vertex (VRTX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
This Magnificent S&P 500 Dividend Stock Is Down 18% -- Time to Buy?
It's been an unusually bad year for this drugmaker, but it's essential to look beyond that.
2 Beaten-Down Stocks With Incredible Upside Potential
These stocks should be able to rebound strongly.
CRISPR Therapeutics Gains 41.4% in 3 Months: How to Play the Stock
CRSP surges 41.4% in three months, fueled by promising CTX310 study data and accelerating Casgevy sales.
What's Wrong With Vertex Pharmaceuticals Stock?
Shares of the pharma company are down 17% in the past 12 months.
Trump 2.0 At 200 Days: Palantir Surges, Tesla Slumps - Palantir Technologies ( NASDAQ:PLTR )
Palantir leads the S&P 500 with a stunning 160% gain in Trump's first 200 days. NRG Energy is the only stock to make the top 20 in both of Trump's terms. Get more market-moving news first with AI-powered analysis that turns noise into opportunity.
Is iShares Biotechnology ETF ( IBB ) a Strong ETF Right Now?
Smart Beta ETF report for ...
